We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

PD-1/PD-L1 Pathway Study on Septic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01161745
Recruitment Status : Completed
First Posted : July 14, 2010
Last Update Posted : July 14, 2010
Information provided by:

Study Description
Brief Summary:
The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.

Condition or disease

Detailed Description:

First, we will detect PD-L1 expression on PBMC of septic patients and healthy controls.

Second, blockade of PD-1/PD-L1 pathway in vitro and stimulate with some biomolecules and then analyze the PBMC function and apoptosis by flow cytometry.

Then, compare with healthy controls and find the differences.

Study Design

Study Type : Observational
Actual Enrollment : 39 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: PD-1/PD-L1 Pathway in T Lymphocyte Apoptosis and Monocyte Dysfunction in Septic Patients
Study Start Date : December 2008
Primary Completion Date : February 2010
Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis
U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Biospecimen Retention:   Samples Without DNA
peripheral venous blood from septic patients and healthy controls, anticoagulate with EDTA-K2

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
patients who develop sepsis

Inclusion Criteria:

  • patients who develop sepsis

Exclusion Criteria:

  • patients with cirrhosis or renal dysfunction
  • patients with dyscrasia
  • patients with autoimmunity diseases
  • patients with severe cardiac and pulmonary diseases
  • patients with hematological diseases
  • patients with diabetes mellitus
  • patients with malignant tumors
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01161745

Sponsors and Collaborators
Changhai Hospital
National Natural Science Foundation of China
Principal Investigator: Xiao-ming Deng, doctor Changhai Hospital, the Second Military Medical University
More Information

Responsible Party: Xiao-ming Deng, Department of Anesthesiology and Intensive Care Unit
ClinicalTrials.gov Identifier: NCT01161745     History of Changes
Other Study ID Numbers: ANETHDEPT-001
First Posted: July 14, 2010    Key Record Dates
Last Update Posted: July 14, 2010
Last Verified: June 2010

Keywords provided by Changhai Hospital:

Additional relevant MeSH terms:
Systemic Inflammatory Response Syndrome
Pathologic Processes